2024
Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Everson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 4800. PMID: 38839763, PMCID: PMC11153605, DOI: 10.1038/s41467-024-48995-7.Peer-Reviewed Original ResearchTLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Everson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 3882. PMID: 38719809, PMCID: PMC11078958, DOI: 10.1038/s41467-024-48073-y.Peer-Reviewed Original ResearchConceptsAutologous tumor lysate-pulsed dendritic cellCD8+ T cellsT cellsPoly-ICLCTLR agonistsMalignant gliomasTumor lysate-pulsed dendritic cellsRandomized phase II trialCD4+ T cellsRandomized phase II clinical trialInterferon responsePhase II clinical trialPoly-ICLC treatmentDendritic cell vaccinesPD-1 expressionPhase II trialInterferon responsive gene expressionSystemic immune responsesImmune cell activationII clinical trialsInduction of interferon-inducible genesDelay disease progressionInterferon gene expressionInterferon-inducible genesPD-1
2019
Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation
Davidson T, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki A, Antonios J, Garcia A, Kotecha N, Bayless N, Nathanson D, Wang A, Everson R, Yong W, Cloughesy T, Liau L, Herold-Mende C, Prins R. Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clinical Cancer Research 2019, 25: 1913-1922. PMID: 30498094, PMCID: PMC6420851, DOI: 10.1158/1078-0432.ccr-18-1176.Peer-Reviewed Original ResearchConceptsPD-1<sup>+</sup> T cellsTumor-infiltrating lymphocytesPD-1<sup>+</sup> tumor-infiltrating lymphocytesPD-1 expressionPD-1T cellsPD-1<sup>+</supMalignant gliomasT lymphocytesEffective antitumor T-cell responsesExpression of markers of activationAntitumor T-cell responsesPD-1 blocking therapyExpression of PD-1Peripheral blood T lymphocytesExpressed PD-1PD-1/PD-L1T cell responsesBlood T lymphocytesIncreased proliferative capacityMarkers of activationPrimary malignant tumorHuman T lymphocytesHallmarks of memoryCentral nervous system
2018
Cell-Based Immunotherapy of Gliomas
Everson R, Antonios J, Liau L. Cell-Based Immunotherapy of Gliomas. Progress In Neurological Surgery 2018, 32: 90-100. PMID: 29990977, DOI: 10.1159/000469683.Peer-Reviewed Original ResearchConceptsCellular immunotherapyImmune cellsDendritic cell (DC)-based vaccinesTreatment of malignant gliomasCellular immunotherapy approachesAntitumor immune cellsAntitumor responseAdoptive transferImmunotherapy approachesActive immunotherapyLive immune cellsMalignant gliomasEffector capabilitiesPassive immunotherapyImmunotherapyImmune responseEx vivoImmune systemGlioma cellsCell typesPatientsGliomaCellsNeoplasms
2017
Detection of immune responses after immunotherapy in glioblastoma using PET and MRI
Antonios J, Soto H, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 10220-10225. PMID: 28874539, PMCID: PMC5617282, DOI: 10.1073/pnas.1706689114.Peer-Reviewed Original ResearchConceptsPD-1Dendritic cellsMAb blockadeTumor lysate-pulsed DC vaccineHost antitumor immune responseTreated with dendritic cellsImmune responseDetection of immune responsesClinical management of patientsPET probeAntitumor immune responseTumor-infiltrating lymphocytesSyngeneic immunocompetent miceContrast enhancementSecondary lymphoid organsContrast-enhanced MRIManagement of patientsProbe uptakeNoninvasive imaging techniquesImmune inflammatory responseDC vaccinesImmunocompetent miceIntracranial tumorsImaging techniquesMalignant gliomasChapter 12 Dendritic Cell Therapy for Brain Tumors
Everson R, Antonios J, Tucker A, Liau L. Chapter 12 Dendritic Cell Therapy for Brain Tumors. 2017, 301-321. DOI: 10.1016/b978-0-12-802420-1.00012-0.Peer-Reviewed Original ResearchDC therapyDendritic cellsClinical trialsEvidence of immune responsesImmune responseLimitations of current treatment optionsTreatment of malignant gliomasDendritic cell therapyAntitumor immune responseAntigen presenting abilityCurrent treatment optionsDevelopment of alternative modalitiesDC vaccinesActive immunotherapyProlonged survivalMalignant gliomasPreclinical modelsTreatment optionsTumor cellsCell therapyClinical effectsVaccine formulationsBrain tumorsImmune systemBrain parenchyma